Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Novartis nixes 6 ph. 1 assets, adds 2 new cancer candidates
The Swiss pharma has scrapped four solid tumor assets and two hematology candidates in a shakeup of its early-stage pipeline.
Darren Incorvaia
Feb 4, 2026 12:09pm
Lisata reclaims China rights to solid tumor candidate from Qilu
Jan 27, 2026 10:12am
BMS pens $850M tumor pact with T-cell engager biotech Janux
Jan 22, 2026 8:35am
Boundless scraps combo treatment of 2 unimpressive cancer drugs
Jan 20, 2026 9:00am
Roche returns to MediLink with $570M near-term payments for ADC
Jan 9, 2026 5:40am
Rakuten lights path to 2028 FDA filing with fresh $100M raise
Jan 7, 2026 9:43am
